nabilone(redirected from Novo-Nadolol)
Also found in: Dictionary, Thesaurus.
Pharmacologic class: Synthetic cannabinoid
Therapeutic class: Antiemetic
Controlled substance schedule II
Pregnancy risk category C
Unclear. Drug has complex effects on CNS, including relaxation, drowsiness, and euphoria; antiemetic effect may result from interaction with cannabinoid receptor system in neural tissues.
Capsules: 1 mg
Indications and dosages
➣ Nausea and vomiting associated with cancer chemotherapy in patients who respond inadequately to conventional antiemetics
Adults: 1 to 2 mg P.O. twice daily; give initial dose 1 to 3 hours before chemotherapy. Maximum daily dose, 6 mg given in divided doses three times daily.
• Hypersensitivity to drug or other cannabinoids
Use cautiously in:
• hepatic or renal impairment, hypertension, cardiac disease, QT interval prolongation, psychiatric disorders (current or previous)
• history of substance abuse
• concurrent use of sedatives, hypnotics, other psychoactive drugs, or CNS depressants
• concurrent alcohol use
• pregnant or breastfeeding patients
• elderly patients
• children (safety and efficacy not established).
• On day of chemotherapy, give 1 to 3 hours before chemotherapeutic drug is administered.
• To minimize adverse reactions, give recommended lower starting dosage and increase dosage as necessary.
• Know that drug may be given two or three times daily during entire course of each chemotherapy cycle and, if needed, for 48 hours after last dose of each chemotherapy cycle.
CNS: drowsiness, euphoria, dysphoria, inebriated feeling, mood swings, irritability, fatigue, malaise, ataxia, headache, poor concentration, disorientation, anxiety, depersonalization, depersonalization syndrome, speech disorder or disturbance, insomnia, abnormal dreams, vertigo, light-headedness, dizziness, orthostatic dizziness, twitching, depression, confusion, asthenia, sedation, hallucinations, paresthesia, memory disturbance, perception disturbance, seizures, dystonia, numbness, akathisia, tremor, incoordination, toxic psychosis, paranoia, apathy, thought disorder, panic disorder, withdrawal, nervousness, phobic neurosis, emotional disorder, hyperactivity, hypotonia, sinus headache
CV: orthostatic hypotension
EENT: visual disturbances, pharyngitis, nasal congestion, dry throat, dry nose, nosebleed, voice change, thick tongue sensation
GI: nausea, dry mouth
GU: increased or decreased urination, urinary retention, urinary frequency
Musculoskeletal: muscle pain, back pain, neck pain, joint pain
Respiratory: dyspnea, wheezing, cough
Skin: excessive sweating, pruritus, rash, photosensitivity
Other: taste changes, increased appetite, fever, hot flashes, chills, unspecified pain, bacterial infection, chest pain, allergic reaction
Drug-drug. Amitriptyline, amoxapine, desipramine, other tricyclics: additive tachycardia, hypertension, drowsiness
Amphetamines, cocaine, other sympathomimetics: additive hypertension, tachycardia, possible cardiotoxicity
Anticholinergics, antihistamines, tri-cyclic antidepressants: increased tachycardia and hypertension
Antihistamines, atropine, scopolamine, other anticholinergics: additive or superadditive tachycardia, drowsiness
Antihistamines, barbiturates, benzodiazepines, buspirone, lithium, muscle relaxants, opioids, other CNS depressants: additive drowsiness and CNS depression
Antipyrine, barbiturates: decreased clearance of these drugs
Disulfiram, fluoxetine: reversible hypomanic reaction
Opioids: cross-tolerance and mutual potentiation
Naltrexone: enhanced nabilone effects
Theophylline: increased theophylline metabolism
Drug-behaviors. Alcohol use: increased positive mood effects, increased CNS depression
Sun exposure: increased risk of skin reactions
• Ensure that patient remains under supervision of responsible adult, especially during initial use and dosage adjustments.
• Monitor vital signs for orthostatic hypotension and tachycardia.
Check for adverse CNS reactions. Report significant depression, paranoid reaction, or emotional lability. Be aware that adverse psychiatric reactions can last for 48 to 72 hours after treatment ends.
• Monitor for excessive use, abuse, or misuse of drug.
• Monitor patient's nutritional and hydration status.
• Instruct patient to take drug on day of chemotherapy 1 to 3 hours before chemotherapeutic drug is scheduled.
• Teach patient about significant CNS side effects (especially mood changes) and cardiovascular side effects. Stress importance of taking drug only as prescribed and needed.
• Inform patient that drug may cause additive CNS depression if used with alcohol or other CNS depressants (such as sleeping pills, tranquilizers, or anxiolytics).
Advise patient, family member, or caregiver to immediately report depression, suicidal thoughts, paranoid reactions, and other serious CNS reactions.
• Caution patient to avoid driving and other hazardous activities until drug effects are known.
• Instruct breastfeeding patient not to use drug while breastfeeding.
• As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs and behaviors mentioned above.